SCHEMBL8916793

SCHEMBL8916793

CCC(=O)[C@H](Cc1ccc(CNC)cc1)NC=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.37
▸ MMP8 P22894 1/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ PARP2 Q9UGN5 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ MMP1 P03956 1/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ MMP3 P08254 1/20 0.34
▸ MMP7 P09237 1/20 0.34
▸ LOXL2 Q9Y4K0 1/20 0.34
▸ ATM Q13315 2/20 0.33
▸ NOS3 P29474 1/20 0.33
▸ NOS1 P29475 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12829849 0.86 SLC6A4 (0.41) SLC6A4MEN1KMT2ATAAR1MMP8
SCHEMBL14853057 0.74 CYP2C19 (0.36) SLC6A4MMP1PPARG
SCHEMBL12524788 0.72 ESR1 (0.51) SLC6A4MEN1KMT2ATAAR1KDM4E
SCHEMBL19033467 0.71 MEN1 (0.56) MEN1KMT2ATAAR1MMP8EPHX1
SCHEMBL6469693 0.71 MEN1 (0.56) MEN1KMT2ATAAR1MMP8EPHX1
SCHEMBL16509238 0.70 FOLH1 (0.47) KMT2ATAAR1MMEACECPA1
SCHEMBL14598298 0.70 TDP1 (0.43) SLC6A4MEN1KMT2AATML3MBTL1
SCHEMBL13827709 0.70 MEN1 (0.59) MEN1KMT2ATAAR1EPHX1MMP2
SCHEMBL19042806 0.70 MEN1 (0.59) MEN1KMT2ATAAR1EPHX1MMP2
SCHEMBL27270915 0.70 MME (0.50) MEN1KMT2ATAAR1EPHX1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188132-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 SLC6A4 3641/4885MEN1 4801/4885KMT2A 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback